Oral Naltrexone and Vivitrol Should Not Be Taken Together
Do not prescribe or administer oral naltrexone and Vivitrol (extended-release injectable naltrexone) concurrently—they contain the same active ingredient and combining them provides no additional therapeutic benefit while unnecessarily increasing drug exposure and potential adverse effects. 1
Why Concurrent Use Is Inappropriate
Same Active Ingredient, Different Delivery Systems
- Both formulations deliver naltrexone, a competitive mu-opioid receptor antagonist that blocks euphoric effects of opioids and reduces alcohol cravings 1
- Oral naltrexone provides 50 mg daily dosing with a plasma half-life of 4 hours and active metabolite (6-β-naltrexol) half-life of 13 hours 2
- Vivitrol delivers 380 mg intramuscularly every 28 days, designed to maintain therapeutic naltrexone levels throughout the month without daily dosing 1, 3
- Adding oral naltrexone to Vivitrol creates redundant opioid receptor blockade without enhancing efficacy 1
No Evidence Supporting Combination Therapy
- Clinical trials of extended-release naltrexone demonstrate efficacy as monotherapy when combined with psychosocial support, with no studies suggesting benefit from adding oral naltrexone 3
- The 24-week phase III trial (ALK21-013) showed Vivitrol 380 mg monthly alone significantly increased opioid abstinence compared to placebo, without requiring supplemental oral dosing 3
- Oral naltrexone was developed specifically to address poor compliance with daily dosing—Vivitrol was subsequently created to eliminate this problem entirely 4, 5
Clinical Algorithm for Naltrexone Formulation Selection
Choose ONE formulation based on patient factors:
Select Vivitrol (380 mg IM monthly) when: 1, 3
- Adherence to daily oral medication is a concern
- Patient prefers monthly injections over daily pills
- Patient has difficulty with pill-taking routines (work schedules, childcare responsibilities)
- Criminal justice involvement where supervised monthly dosing is advantageous
Select oral naltrexone (50 mg daily) when: 1, 6
- Patient may require opioid analgesia in near future (can discontinue 2-3 days before surgery vs. 24-30 days for Vivitrol) 2, 7
- Patient prefers flexibility to stop medication quickly if needed
- Cost is prohibitive for injectable formulation
- Patient is highly motivated and demonstrates good medication adherence
Critical Safety Considerations
- Both formulations require patients to be completely opioid-free for 7-10 days before initiation to avoid precipitating severe withdrawal 2
- Baseline liver function tests must be obtained and repeated every 3-6 months due to hepatotoxicity risk at supratherapeutic doses 1
- Neither formulation can be used in patients requiring opioid analgesics, as naltrexone completely blocks opioid pain relief 7
- Patients discontinuing either formulation face markedly increased overdose risk due to loss of opioid tolerance during treatment 1, 7
Common Pitfall to Avoid
Do not attempt to "boost" Vivitrol effectiveness by adding oral naltrexone—the injectable formulation already provides complete opioid receptor blockade throughout the dosing interval, and pharmacokinetic studies confirm therapeutic naltrexone levels persist for the entire 28-day cycle. 4, 8 Adding oral doses creates unnecessary drug accumulation without improving outcomes and may increase adverse events such as nausea, hepatic enzyme abnormalities, and injection-site reactions. 3
Switching Between Formulations
If transitioning from Vivitrol to oral naltrexone, oral dosing can begin immediately without waiting for the extended-release formulation to clear, since both contain identical active ingredients. 2 However, switching from oral to injectable requires no washout period—simply administer the first Vivitrol injection and discontinue oral tablets. 1